

## **Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy.**

*Pourshabanen P et al. Diabetes Metab Syndr 2019;13(1): 132-136.*

- Diabetic nephropathy means albuminuria greater than 30 mg/day and it affects about one third of diabetic patients.
- The study was conducted to investigate the effect of pioglitazone on reduction in proteinuria in type 2 DM patients and nephropathy.
- In a double blind trial on 76 patients with type 2 DM with proteinuria greater than 250 mg/d were enrolled in 2 equal groups; one were administered 15mg/d of pioglitazone and the other placebo and the urinary protein excretion over 24h in all the patients was measured.
- Pioglitazone had considerable effects on FBS, HbA1c & Triglycerides which were statistically significant.
- After 2 months the urinary protein excretion in the pioglitazone was significantly reduced as compared to the control group.

**Low dose of pioglitazone is an effective, safe and inexpensive method in reducing of proteinuria in type2 diabetic patients with nephropathy.**